Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Conditions
Interventions
Placebo
Lanadelumab
Locations
45
United States
Clinical Research Center of Alabama
Birmingham, Alabama, United States
Medical Research of Arizona
Scottsdale, Arizona, United States
University of California San Diego
San Diego, California, United States
AIRE Medical of Los Angeles
Santa Monica, California, United States
Allergy and Asthma Clinical Research Inc
Walnut Creek, California, United States
Asthma and Allergy Associates, PC
Colorado Springs, Colorado, United States
Start Date
May 4, 2020
Primary Completion Date
October 20, 2022
Completion Date
October 20, 2022
Last Updated
December 27, 2023
NCT07298447
NCT06960213
NCT06842823
NCT06573723
NCT06634420
NCT05392114
Lead Sponsor
Takeda
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions